Therapeutic vaccine platform to boost immune responses in Tuberculosis

L2 Diagnostics, Llc, New Haven CT

Investigators

Abstract

The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to build a prototype mRNA vaccine containing Mtb-antigens as a safe and effective multivalent therapeutic vaccine against tuberculosis.